Takeda Pharmaceutical Limited's Customers Performance

Name: Takeda Pharmaceutical Limited Customers by Division and Industry - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use

TAK

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.


TAK's Source of Revenues		During the corresponding time, Takeda Pharmaceutical Company Limited recorded a revenue increase by 0.06 % year on year, While revenue at the Takeda Pharmaceutical Company Limited's corporate clients • List of TAK Customers

for the same period Takeda Pharmaceutical Company Limited recorded revenue increase by 0.06 % year on year,

• List of TAK Customers

Takeda Pharmaceutical Limited's Business Units


Sales of pharmaceutical products	98.13 %	of total Revenue
Out-licensing and service income	1.87 %	of total Revenue
Total Gastroenterology	29.62 %	of total Revenue
ENTYVIO	19.95 %	of total Revenue
GATTEX REVESTIVE	3.19 %	of total Revenue
TAKECAB VOCINTI	2.85 %	of total Revenue
PANTOLOC CONTROLOC	0.97 %	of total Revenue
DEXILANT	0.84 %	of total Revenue
EOHILIA	0.12 %	of total Revenue
Others	5.19 %	of total Revenue
Total Rare Diseases	16.43 %	of total Revenue
TAKHZYRO	4.87 %	of total Revenue
ADVATE	2.44 %	of total Revenue
ELAPRASE	2.12 %	of total Revenue
REPLAGAL	1.7 %	of total Revenue
ADYNOVATE ADYNOVI	1.41 %	of total Revenue
VPRIV	1.17 %	of total Revenue
LIVTENCITY	0.72 %	of total Revenue
ADZYNMA	0.15 %	of total Revenue
Total PDT	22.54 %	of total Revenue
Immunoglobulin	16.54 %	of total Revenue
Albumin	3.09 %	of total Revenue
Total Oncology	12.23 %	of total Revenue
ADCETRIS	2.82 %	of total Revenue
LEUPLIN ENANTONE	2.6 %	of total Revenue
NINLARO	1.99 %	of total Revenue
ICLUSIG	1.54 %	of total Revenue
FRUZAQLA	1.05 %	of total Revenue
ALUNBRIG	0.8 %	of total Revenue
Total Vaccines	1.21 %	of total Revenue
QDENGA	0.78 %	of total Revenue
Total Neuroscience	12.35 %	of total Revenue
VYVANSE ELVANSE	7.65 %	of total Revenue
TRINTELLIX	2.74 %	of total Revenue
ADDERALL XR	0.62 %	of total Revenue
Total Other	5.62 %	of total Revenue
AZILVA	0.26 %	of total Revenue
FOSRENOL	0.17 %	of total Revenue
Japan	1433.88 %	of total Revenue
U S	8153.99 %	of total Revenue
Europe and Canada	3615.87 %	of total Revenue
Latin America	808.14 %	of total Revenue
China	657.01 %	of total Revenue
Asia excluding Japan China	340.57 %	of total Revenue
Russia CIS	247.93 %	of total Revenue
Other	441.51 %	of total Revenue
Cencora Group Customer risk concentration net sales	12.59 %	of total Revenue
McKesson Group Customer risk concentration net sales	12.93 %	of total Revenue

Select the Relationship:

Customers ▼

Select the Category:

Comparison ▼

Customers ▼

Basic Report▼

Takeda Pharmaceutical Limited's Comment on Sales, Marketing and Customers

TAK's Stock Performance relative to it's Customers

TAK's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Takeda Pharmaceutical Company Limited	29,345.46	29,183.90	688.86	47,000
SUBTOTAL	0.00	0.00	0.00	-

Sources: Takeda Pharmaceutical Company Limited’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Takeda Pharmaceutical Company Limited’s corporate clients.
For your research, we’ve provided 9 tables on Takeda Pharmaceutical Company Limited corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.